Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The phiC31 integrase system for gene therapy.

Michele P Calos¹

¹Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305-5120, USA. calos@stanford.edu

Current Gene Therapy

|December 16, 2006

Summary

The phiC31 integrase system enables precise gene insertion into mammalian genomes for sustained gene therapy. This technology shows significant promise for various preclinical applications and future therapeutic success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Knock-in Blunt Ligation Utilizing CRISPR/Cas9.

Bio-protocol·2021

Same author

Nucleofection of phiC31 Integrase Protein Mediates Sequence-Specific Genomic Integration in Human Cells.

Journal of molecular biology·2020

Same author

Plasmid-Mediated Gene Therapy in Mouse Models of Limb Girdle Muscular Dystrophy.

Molecular therapy. Methods & clinical development·2020

Same author

Lack of RAC.

Molecular therapy : the journal of the American Society of Gene Therapy·2018

Same author

DNA-Mediated Gene Therapy in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Molecular therapy. Methods & clinical development·2017

Same author

Use of the DICE (Dual Integrase Cassette Exchange) System.

Methods in molecular biology (Clifton, N.J.)·2017

Area of Science:

Molecular Biology
Gene Therapy
Genomics

Background:

The phiC31 integrase system offers a novel approach for gene therapy.
It facilitates targeted integration of plasmid DNA into mammalian genomes.

Purpose of the Study:

To review the phiC31 integrase system's mechanism and genomic targets.
To summarize preclinical gene therapy applications and evaluate safety.
To compare its strengths and limitations against other gene therapy methods.

Main Methods:

Review of scientific literature on phiC31 integrase.
Analysis of integration site preferences in human cells.
Summary and evaluation of preclinical in vivo and ex vivo studies.

Main Results:

phiC31 integrase achieves site-specific DNA integration, ensuring robust, long-term transgene expression.
Successful preclinical applications demonstrated in liver, muscle, eye, joint, skin, and T cells.
The system's safety profile is evaluated, highlighting its advantages and disadvantages.

Conclusions:

The phiC31 integrase system is a promising technology for gene therapy.
Ongoing improvements are enhancing its potential for clinical success.
It offers a viable strategy for advanced gene therapy applications.

Related Experiment Videos